Shanghai Microport Endovascular Medtech(Group) Co., Ltd. (688016.SH): plans to implement mid-term dividend in 2024.
On July 10th, Gelunhui reported that Shanghai Microport Endovascular Medtech (Group) Co., Ltd. (688016.SH) plans to implement a mid-year dividend in 2024 based on the actual situation and future development needs of the company. If there are distributable profits in the first half of 2024, the mid-year dividend in 2024 will not be less than 50% of the net income attributable to the shareholders of the listed company in the first half of 2024.
MicroPort Scientific Forecasts Decline in Net Loss for H1 on Higher Revenue
MicroPort Scientific (HKG:0853) forecasts a "significant" decline in its net loss for the six months ended June 30 due to a 17% rise in revenue, according to a Monday filing with the Hong Kong Stock
Shanghai MicroPort Endovascular MedTech (SHSE:688016) Is Reinvesting At Lower Rates Of Return
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Amongst other things, we'll want to see two things; firstly, a growing return on
MicroPort Endovascular Expects Up to 30% Profit Growth in H1; Shares Rise 6%
Shanghai MicroPort Endovascular MedTech (SHA:688016) expects its net profit attributable to the equity owners for the six months ended June 30 to be in the range of 777.0 million yuan and 808.1 millio
Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd.: Voluntary disclosure announcement of the 2024 semi-annual performance forecast.
Selected announcements from geloncize: shanghai microport endovascular medtech(group)co.,ltd. expects net income to increase by 40% to 50% year-on-year in the first half of the year; cofco biotechnology plans to invest 185 million yuan to expand its Cheng
Investment project: Cofco Biotechnology (000930.SZ): plans to invest 185 million yuan to expand Chengdu company's annual production of 150,000 tons of starch sugar projects. Cofco Biotechnology (000930.SZ) announced that in order to improve the industrial layout of starch sugar business, enhance market share, and improve market competitiveness, the company plans to invest in expanding the COFCO Biochemical (Chengdu) Co., Ltd.'s 150,000 tons/year starch sugar project. The total investment is approximately 185,261.3 million yuan (the final total investment of the project is subject to actual investment). The construction period is 18 months from the date of project approval to successful commissioning. Contract Award: Hongrun Construction Group (00206
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (688016.SH): Subsidiary intends to acquire 72.37% equity of OMD.
On July 1st, Gelunhui reported that its wholly-owned subsidiary, MICROPORT ENDOVASTEC B.V. (referred to as "Heart of the Netherlands"), plans to use its own funds of $65 million (calculated based on the RMB exchange rate announced by the People's Bank of China on July 1, 2024, equivalent to approximately RMB 463,222,500) to acquire Earl Intellect Limited and Turbo Heart Limited's combined holdings in Shanghai Microport Endovascular Medtech(Group) Co., Ltd.
Microport (00853.HK) expects Shanghai Microport Endovascular Medtech (Group) Co., Ltd.'s net income to increase by about 40%-50% in the first half of the year.
MicroPort (00853.HK) announced that its subsidiary, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. ("MicroPort Endovascular"), is expected to record profit growth for the six months ended June 30, 2024. The Group holds a 40.32% equity interest in MicroPort Endovascular, and its performance is consolidated into the company's financial statements. MicroPort Endovascular's shares are listed on the STAR Market of the Shanghai Stock Exchange. For the six months ended June 30, 2024, MicroPort Endovascular is expected to achieve revenue of RMB 777,028,100 to RMB 808,109,200.
Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. (688016.SH) will have approximately 16.01 million restricted shares listed for circulation on June 24th.
Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. (688016.SH) issued an announcement, the restricted shares to be listed this time are the stocks issued to specific objects...
Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
It is hard to get excited after looking at Shanghai MicroPort Endovascular MedTech's (SHSE:688016) recent performance, when its stock has declined 12% over the past month. However, stock prices are
Cardiac Medicine (688016.SH): The venous venous filter obtained a medical device registration certificate
On June 6th, Gelonhui reported that Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. (688016.SH) has been awarded a medical device registration certificate from the National Medical Products Administration for its vena cava filter product. The acquisition of the medical device registration certificate further enriches the company's existing product categories, expands the company's product line layout in the peripheral field, further promotes the company's market expansion in the peripheral field, continuously meets market demand, and promotes the steady growth of the company's overall sales revenue and profits, further deepening the company's influence and competitiveness in the market of intervention in the aorta and peripheral blood vessels.
Cathay Pacific Junan: The valuation level of the normalized mining industry is expected to rise
The Zhitong Finance App learned that Guotai Junan released a research report saying that in recent years, the quality of collection has been improved and expanded. Along with this, the design of collection rules has been continuously improved, and the results are more moderate and predictable. The results of this joint China Mining contract renewal have provided further verification. As the negative effects of traditional product collection are gradually clarified, emerging varieties are rapidly being admitted to hospital through collection. The number of surgeries is expected to continue to grow under the combined impetus of factors such as an aging population, increased public health awareness, and more mature procedures. The high-value consumables industry is also expected to continue to flourish on a new base, and the industry's valuation level is expected to rise. Maintain Elken Healthcare (0178
Insufficient Growth At Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016) Hampers Share Price
Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) price-to-earnings (or "P/E") ratio of 26.2x might make it look like a buy right now compared to the market in China, where around half
Heart Heart Medical (688016.SH) 2023 equity distribution: 3 yuan per share, free 0.49 shares, shares registered on May 13
Heart Heart Healthcare (688016.SH) issued the 2023 equity distribution implementation notice. This time, profits will be distributed to Israel...
Cardiac Healthcare (688016.SH) announced first-quarter results, net profit of 184 million yuan, up 47.62% year-on-year
Heart Heart Healthcare (688016.SH) disclosed its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
Is Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016) Worth CN¥178 Based On Its Intrinsic Value?
Key Insights Shanghai MicroPort Endovascular MedTech's estimated fair value is CN¥146 based on 2 Stage Free Cash Flow to Equity Current share price of CN¥178 suggests Shanghai MicroPort Endovascular
Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Earnings Are Weaker Than They Seem
Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016) just reported some strong earnings, and the market reacted accordingly with a healthy uplift in the share price. However, we think that
Analysts Have Made A Financial Statement On Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Annual Report
It's been a good week for Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016) shareholders, because the company has just released its latest yearly results, and the shares gained 3.7% to C
Minimally Invasive Healthcare (00853): Cardiac Medical Technology's net profit to the mother in 2023 was 492 million yuan, up 37.98% year-on-year
Minimally Invasive Healthcare (00853) released Affiliated Cardiac Medical Technology, which has been reviewed for 12 months ending December 31, 2023...
Shanghai MicroPort Endovascular MedTech (SHSE:688016) Could Easily Take On More Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, whe
No Data